Recently featured in
Why do so many US and global biotech firms bring their early-stage clinical trials to Australia?
Government Grant Access
43.5% Government R&D tax incentive (even for foreign companies)
Fast, High-Quality Research
Fast start-up time without sacrificing quality – 8-12 weeks on average (no IND required)
FDA Regulatory Expertise
iNGENū's in-house regulatory team specializes in US FDA Pre-INDs and IND submissions
Diverse Therapeutic Specialty Leaders
Our team comprises physician and scientific specialists in a wide variety of areas
Our trusted partners
Our core mission is to create access to high quality clinical research globally by removing financial and other unnecessary barriers.